Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: HCV Infection
Interventions: ABT-450, ritonavir, placebo for ABT-450, Placebo for ritonavir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: ORMD-0801, Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Glycemic Control
Interventions: Fasiglifam (TAK-875), Sitagliptin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 58
States / cities: Muscle Shoals, Alabama • Mesa, Arizona • Peoria, Arizona + 55 more

Conditions: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more

Conditions: BK Virus Nephropathy, BK Virus Infection
Interventions: Posoleucel (formerly known as ALVR105) cells, Placebo (visually identical to Posoleucel); Biological
Lead sponsor: AlloVir; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 33
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 27 more

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions: parsaclisinib, placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Whittier, California • Miami, Florida + 6 more

Conditions: SARS-CoV-2 Infection
Interventions: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant); Biological · Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Pain, Inflammation
Interventions: Nepafenac PPDS, Placebo PPDS; Combination Product
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 22 Years to 99 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Edgewood, Kentucky • Garden City, New York • Mt. Pleasant, South Carolina

Conditions: Oral Mucositis
Interventions: ALD518, 0.9% saline; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more

Conditions: Healthy Participants
Interventions: BLU-808, Placebo, Midazolam; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Actinic Keratosis
Interventions: Imiquimod cream, Placebo cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 22 more

Conditions: Bipolar Disorder, Bipolar Depression, Depression
Interventions: quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity; Drug · Behavioral
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • National City, California + 25 more

Conditions: Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions: Azetukalner, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 34
States / cities: Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 29 more

Conditions: Nausea and Vomitting
Interventions: TAK-951, TAK-951 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
Interventions: RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 60 Years and older
Enrollment: 646 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more

Conditions: Frontotemporal Dementia
Interventions: Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001, Part 2 (OLE Treatment) - Placebo Switched to AL001; Drug
Lead sponsor: Alector Inc.; Industry
Eligibility: 25 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more

Conditions: Systemic Sclerosis, Ulcers
Interventions: macitentan 3mg, macitentan 10mg, placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • Aventura, Florida + 12 more

Conditions: Fragile X Syndrome
Interventions: STX107; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Schizophrenia
Interventions: RO4917838, Placebo, Standard antipsychotic therapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Granada Hills, California • Los Angeles, California • Oceanside, California + 10 more

Conditions: Type 2 Diabetes Mellitus
Interventions: LGD-6972, Placebo (Captisol®); Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Alzheimer's Disease
Interventions: BMS-708163, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 30 more

Conditions: Perimenopause, Women Health
Interventions: Shatavari (Asparagus racemosus) Root Extract, Placebo Capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 40 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoarthritis of the Knee
Interventions: PENNSAID Gel, Vehicle; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 26
States / cities: Tucson, Arizona • Sacramento, California • Clearwater, Florida + 22 more

Conditions: Hypertension
Interventions: Firibastat, Placebo; Drug
Lead sponsor: Quantum Genomics SA; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Huntington Beach, California • Tustin, California + 11 more

Search by objective public record fields.

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Study of BLU-808 in Healthy Adult Participants

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

Seroquel in Bipolar Depression Versus SSRI

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

Shatavari Root Extract for Perimenopausal Symptoms

Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis

Firibastat in Treatment-resistant Hypertension